Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17247793 | 0.93 | USP2 (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14388558 | 0.91 | USP2 (0.44) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9042133 | 0.91 | USP2 (0.44) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL31495674 | 0.87 | TSHR (0.56) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL15884717 | 0.86 | KDM4E (0.40) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL8133072 | 0.79 | KDM4E (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3816311 | 0.79 | NAMPT (0.34) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.77 | USP2 (0.75) | USP2TSHRKDM4EALDH1A1LMNA | |
| Ethane Dimethane Sulfonate SCHEMBL17022719 | 0.75 | USP2 (0.63) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL23070986 | 0.74 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4549438-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-115919859-A | Pharmaceutical composition of heteroaryl derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | USP2 3328/4885TSHR 81/4885KDM4E 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.